BenevolentAI Investor Day Presentation Deck
BEN-2293 - A potent PanTrk antagonist developed to relieve
inflammation and provide rapid itch resolution Atopic Dermatitis
·
●
BEN-2293 is a PanTrk inhibitor targeting TrkA, B and C
receptors. The Trk receptors were identified as part of an
effort to find mediators of both itch and inflammation
in AD. Using our Molecular Design expertise we were
able to design a PanTrk inhibitor, equipotent against the
3 receptors
BEN-2293 is expected to treat atopic dermatitis by:
inhibiting itch signaling and blocking nerve sensitization
(TrkA) in addition to inhibiting Th1 and Th2-mediated
dermal inflammation (TrkB, TrkC)
BEN-2293 will target Mild, Moderate and Severe Atopic
Dermatitis patients, addressing unmet need in the
treatment of mild to moderate Atopic Dermatitis as a
steroid sparing alternative and in more severe patients
undergoing treatment with biologics (e.g. dupilumab)
that require add-on treatment
NGF
Y
TrkA
PIP2
PLC
BDNF
TrkB
NTF-3
4
TrkC
GAB1
Neurotrophins bind to high affinity
receptors (TrkA, B and C), directly
activating both inflammation and itch
signalling which propagates a cycle of
itching and scratching.
Key: Tropomyosin-related kinase (Trk) receptor tyrosine kinase family, namely TrkA, TrkB, and TrkC; Nerve Growth Factor (NGF); Brain Derived Neurotrophic Factor (BDNF); Neurotrophin-3 (NTF-3)/NT3 Benevolent 43
Image source: Amatu et al. ESMO Open 2016View entire presentation